Pertti J Neuvonen

Summary

Affiliation: Helsinki University Central Hospital
Country: Finland

Publications

  1. ncbi request reprint Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics
    Pertti J Neuvonen
    University of Helsinki and Helsinki University Central Hospital, Department of Clinical Pharmacology, PO Box 705, FIN 00029 HUS, Helsinki, Finland
    Curr Opin Investig Drugs 11:323-32. 2010
  2. doi request reprint Towards safer and more predictable drug treatment--reflections from studies of the First BCPT Prize awardee
    Pertti J Neuvonen
    Department of Clinical Pharmacology, University of Helsinki, and HUSLAB, Helsinki University Central Hospital, Helsinki, Finland
    Basic Clin Pharmacol Toxicol 110:207-18. 2012
  3. ncbi request reprint Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin
    Pertti J Neuvonen
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Clin Pharmacokinet 47:463-74. 2008
  4. ncbi request reprint Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance
    Pertti J Neuvonen
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Clin Pharmacol Ther 80:565-81. 2006
  5. doi request reprint CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe
    Janne T Backman
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki
    Drug Metab Dispos 37:2359-66. 2009
  6. doi request reprint Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide
    Annikka Kalliokoski
    Department of Clinical Pharmacology, Helsinki University Central Hospital, FIN 00029 HUS, Finland
    J Clin Pharmacol 48:311-21. 2008
  7. ncbi request reprint Cyclosporine markedly raises the plasma concentrations of repaglinide
    Lauri I Kajosaari
    Department of Clinical Pharmacology, University of Helsinki, and Helsinki University Central Hospital
    Clin Pharmacol Ther 78:388-99. 2005
  8. pmc Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide
    Mikko Niemi
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Br J Clin Pharmacol 60:208-17. 2005
  9. doi request reprint Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms
    Samuel Fanta
    Department of Clinical Pharmacology, University of Helsinki, and Pediatric Nephrology and Transplantation, Hospital for Children and Adolescents, Helsinki University Central Hospital, Helsinki, Finland
    Pharmacogenet Genomics 18:77-90. 2008
  10. ncbi request reprint Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen
    Aleksi Tornio
    Department of Clinical Pharmacology, University of Helsinki, Haartmaninkatu 4, 00290, Helsinki, Finland
    Eur J Clin Pharmacol 63:463-9. 2007

Detail Information

Publications90

  1. ncbi request reprint Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics
    Pertti J Neuvonen
    University of Helsinki and Helsinki University Central Hospital, Department of Clinical Pharmacology, PO Box 705, FIN 00029 HUS, Helsinki, Finland
    Curr Opin Investig Drugs 11:323-32. 2010
    ..An understanding of the mechanisms of statin interactions will help to minimize drug interactions and to develop statins that are less prone to adverse interactions...
  2. doi request reprint Towards safer and more predictable drug treatment--reflections from studies of the First BCPT Prize awardee
    Pertti J Neuvonen
    Department of Clinical Pharmacology, University of Helsinki, and HUSLAB, Helsinki University Central Hospital, Helsinki, Finland
    Basic Clin Pharmacol Toxicol 110:207-18. 2012
    ..Both drug interactions and pharmacogenetics can modify the activity of cell membrane transporters and cause variability in the pharmacokinetics of and response to their substrate drugs...
  3. ncbi request reprint Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin
    Pertti J Neuvonen
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Clin Pharmacokinet 47:463-74. 2008
    ..On the pharmacokinetic basis, fluvastatin and pravastatin can be better choices than simvastatin or lovastatin for an OTC statin...
  4. ncbi request reprint Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance
    Pertti J Neuvonen
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Clin Pharmacol Ther 80:565-81. 2006
    ..Knowledge of the pharmacokinetic and pharmacodynamic properties of lipid-lowering drugs and their interaction mechanisms helps to avoid adverse interactions, without compromising therapeutic benefits...
  5. doi request reprint CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe
    Janne T Backman
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki
    Drug Metab Dispos 37:2359-66. 2009
    ..The estimated CYP2C8 half-life will be useful for in vitro-in vivo extrapolations of drug-drug interactions involving induction or mechanism-based inhibition of CYP2C8...
  6. doi request reprint Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide
    Annikka Kalliokoski
    Department of Clinical Pharmacology, Helsinki University Central Hospital, FIN 00029 HUS, Finland
    J Clin Pharmacol 48:311-21. 2008
    ..Thus, in contrast to repaglinide, the disposition of nateglinide is unaffected by the SLCO1B1 c.521T>C polymorphism...
  7. ncbi request reprint Cyclosporine markedly raises the plasma concentrations of repaglinide
    Lauri I Kajosaari
    Department of Clinical Pharmacology, University of Helsinki, and Helsinki University Central Hospital
    Clin Pharmacol Ther 78:388-99. 2005
    ..We studied the effects of cyclosporine (INN, ciclosporin), an inhibitor of CYP3A4 and OATP1B1, on the pharmacokinetics and pharmacodynamics of repaglinide...
  8. pmc Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide
    Mikko Niemi
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Br J Clin Pharmacol 60:208-17. 2005
    ..Our aim was to investigate the effects of the gemfibrozil-itraconazole combination on the pharmacokinetics and pharmacodynamics of another meglitinide analogue, nateglinide, which is metabolized by CYP2C9 and CYP3A4...
  9. doi request reprint Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms
    Samuel Fanta
    Department of Clinical Pharmacology, University of Helsinki, and Pediatric Nephrology and Transplantation, Hospital for Children and Adolescents, Helsinki University Central Hospital, Helsinki, Finland
    Pharmacogenet Genomics 18:77-90. 2008
    ....
  10. ncbi request reprint Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen
    Aleksi Tornio
    Department of Clinical Pharmacology, University of Helsinki, Haartmaninkatu 4, 00290, Helsinki, Finland
    Eur J Clin Pharmacol 63:463-9. 2007
    ..We studied the possible effect of gemfibrozil, an in vivo inhibitor of CYP2C8, on the pharmacokinetics of ibuprofen in healthy volunteers...
  11. ncbi request reprint Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide
    Lauri I Kajosaari
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University, Central Hospital, Helsinki, Finland
    Eur J Clin Pharmacol 62:217-23. 2006
    ..In patients with type 2 diabetes, the pioglitazone-repaglinide combination has acted synergistically on glycaemic parameters. Our aim was to determine whether pioglitazone increases the plasma concentrations of repaglinide...
  12. ncbi request reprint Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin
    Lauri I Kajosaari
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Basic Clin Pharmacol Toxicol 97:249-56. 2005
    ..Rifampicin competitively inhibits both CYP2C8 and CYP3A4, which can counteract its inducing effect in humans...
  13. ncbi request reprint Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone
    Aleksi Tornio
    Department of Clinical Pharmacology, University of Helsinki, Helsinki University Central Hospital, Helsinki, Finland
    Drug Metab Dispos 36:73-80. 2008
    ..Trimethoprim inhibited M-IV formation in vitro (inhibition constant 38.2 muM), predicting the in vivo interaction. In conclusion, drug interactions and pharmacogenetics affecting the CYP2C8 enzyme may change the safety of pioglitazone...
  14. pmc No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin
    Jenni E Keskitalo
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki FI 00029, Finland
    Br J Clin Pharmacol 68:207-13. 2009
    ..This study aimed to investigate possible effects of ABCB1 genotype on fluvastatin, pravastatin, lovastatin, and rosuvastatin pharmacokinetics...
  15. doi request reprint Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations
    Tiina Karonen
    Department of Clinical Pharmacology, University of Helsinki and HUSLAB, Helsinki University Central Hospital, PO Box 705, FI 00029 Helsinki, Finland
    Eur J Clin Pharmacol 68:681-8. 2012
    ..To investigate the contribution of CYP2C9 and CYP3A4 to zafirlukast metabolism, we studied the effects of fluconazole and itraconazole on its pharmacokinetics (PK)...
  16. ncbi request reprint Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism
    Marika T Granfors
    Department of Clinical Pharmacology, University of Helsinki, FIN 00290 Helsinki, Finland
    Clin Pharmacol Ther 76:598-606. 2004
    ..The fluoroquinolone antibiotic ciprofloxacin is only a moderately potent inhibitor of CYP1A2. Our objective was to study the extent and mechanism of a possible interaction of ciprofloxacin with tizanidine...
  17. pmc Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes
    Mia Hedman
    Hospital for Children and Adolescents, University of Helsinki, Helsinki, Finland
    Br J Clin Pharmacol 61:706-15. 2006
    ....
  18. doi request reprint Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin
    Jenni E Keskitalo
    Department of Clinical Pharmacology, Helsinki University Central Hospital, Finland
    Pharmacogenomics 10:1617-24. 2009
    ..This study aimed to investigate possible effects of the ABCG2 c.421C>A (p.Gln141Lys; rs2231142) genotype on fluvastatin, pravastatin and simvastatin pharmacokinetics...
  19. ncbi request reprint Effect of fluvoxamine and erythromycin on the pharmacokinetics of oral lidocaine
    Mika H Isohanni
    Department of Anaesthesia, Diacor Hospital, Helsinki, Finland
    Basic Clin Pharmacol Toxicol 99:168-72. 2006
    ..The concomitant use of both fluvoxamine and a CYP3A4 inhibitor like erythromycin may further increase plasma lidocaine concentrations...
  20. doi request reprint Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide
    Annikka Kalliokoski
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Pharmacogenet Genomics 18:937-42. 2008
    ..The aim of this study was to investigate whether the SLCO1B1*1B haplotype affects the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide...
  21. doi request reprint Itraconazole, a P-glycoprotein and CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renin-inhibiting effect of aliskiren
    Tuija Tapaninen
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, FI 00029 HUS, Finland
    J Clin Pharmacol 51:359-67. 2011
    ..Concomitant use of aliskiren and itraconazole is best avoided...
  22. ncbi request reprint Tolfenamic acid is a potent CYP1A2 inhibitor in vitro but does not interact in vivo: correction for protein binding is needed for data interpretation
    Marjo J Karjalainen
    Department of Clinical Pharmacology, University of Helsinki, Helsinki, Finland
    Eur J Clin Pharmacol 63:829-36. 2007
    ..Our aim was to correlate the in vitro and in vivo CYP1A2 inhibition potential of tolfenamic acid, an NSAID highly (99.7%) bound to plasma proteins, to study the significance of protein binding of inhibitor in metabolic drug interactions...
  23. ncbi request reprint Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics
    Mikko Niemi
    Department of Clinical Pharmacology, University of Helsinki University Central Hospital, Helsinki
    Clin Pharmacol Ther 77:468-78. 2005
    ....
  24. doi request reprint SLCO2B1 c.935G>A single nucleotide polymorphism has no effect on the pharmacokinetics of montelukast and aliskiren
    Tuija Tapaninen
    Department of Clinical Pharmacology, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland
    Pharmacogenet Genomics 23:19-24. 2013
    ..Our aim was to examine the possible effects of the SLCO2B1 c.935G>A SNP on the single-dose pharmacokinetics of the suggested OATP2B1 substrates montelukast and aliskiren...
  25. doi request reprint Dose-dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil doses
    Johanna Honkalammi
    Department of Clinical Pharmacology, University of Helsinki, and HUSLAB Laboratory Services, Helsinki University Central Hospital, Helsinki, Finland
    Drug Metab Dispos 39:1977-86. 2011
    ..In clinical drug-drug interaction studies, a single 900-mg dose of gemfibrozil can be used to achieve nearly complete inactivation of CYP2C8...
  26. ncbi request reprint Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction
    Marika T Granfors
    Department of Clinical Pharmacology, University of Helsinki, and Helsinki University Central Hospital, Helsinki, Finland
    Clin Pharmacol Ther 75:331-41. 2004
    ..Our objective was to study the effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of tizanidine, a centrally acting skeletal muscle relaxant...
  27. ncbi request reprint Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide
    Mikko Niemi
    Department of Clinical Pharmacology, Helsinki University Central Hospital, PO Box 340, FI 00029, HUS, Finland
    Eur J Clin Pharmacol 62:463-72. 2006
    ..Our aim was to investigate the effects of itraconazole, an inhibitor of CYP3A4 and P-glycoprotein, and gemfibrozil, an inhibitor of CYP2C8, on the pharmacokinetics of loperamide...
  28. ncbi request reprint Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro
    Marika T Granfors
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Basic Clin Pharmacol Toxicol 98:79-85. 2006
    ....
  29. ncbi request reprint Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide
    Lauri I Kajosaari
    Department of Clinical Pharmacology, University of Helsinki, and Helsinki University Central Hospital, Helsinki, Finland
    Clin Pharmacol Ther 79:231-42. 2006
    ..We studied the effects of telithromycin, montelukast, and the combination of telithromycin and montelukast on the pharmacokinetics and pharmacodynamics of repaglinide...
  30. ncbi request reprint Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone
    Tiina Jaakkola
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, P O Box 340, 00029 HUS, Helkinski, Finland
    Eur J Clin Pharmacol 62:503-9. 2006
    ..Our objective was to determine whether montelukast and zafirlukast increase the plasma concentrations of pioglitazone in humans...
  31. ncbi request reprint SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin
    Mikko Niemi
    Department of Clinical Pharmacology, University of Helsinki, Helsinki University Central Hospital, Helsinki, Finland
    Clin Pharmacol Ther 80:356-66. 2006
    ..Our aim was to compare the effects of SLCO1B1 polymorphism on the pharmacokinetics of pravastatin and fluvastatin...
  32. pmc The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range
    Annikka Kalliokoski
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Br J Clin Pharmacol 66:818-25. 2008
    ..To establish whether the effect of SLCO1B1[encoding organic anion transporting polypeptide 1B1 (OATP1B1)] c.521T-->C (p.Val174Ala) polymorphism on the pharmacokinetics of repaglinide is dose-dependent...
  33. doi request reprint SLCO1B1 polymorphism and oral antidiabetic drugs
    Annikka Kalliokoski
    Research Department, Social Insurance Institution, Helsinki, Finland
    Basic Clin Pharmacol Toxicol 107:775-81. 2010
    ..Therefore, SLCO1B1 polymorphism unlikely affects the response to these antidiabetics. Possible effects of SLCO1B1 polymorphism on sulfonylureas remain to be investigated...
  34. ncbi request reprint Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone
    Tiina Jaakkola
    Department of Clinical Pharmacology, PO Box 340, FIN 00290 HUS, Finland
    Clin Pharmacol Ther 77:404-14. 2005
    ..Our objective was to study the effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone to determine the role of these enzymes in the fate of pioglitazone in humans...
  35. ncbi request reprint Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics
    Mikko Niemi
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Pharmacogenet Genomics 16:801-8. 2006
    ..Our aim was to investigate possible effects of sequence variations in ABCC2, encoding the multidrug resistance-associated protein 2 (MRP2), on the pharmacokinetics of the MRP2 substrate pravastatin...
  36. pmc CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast
    Tiina Karonen
    Department of Clinical Pharmacology, University of Helsinki and HUSLAB, Helsinki University Central Hospital, P O Box 705, FI 00029 HUS, Finland
    Br J Clin Pharmacol 73:257-67. 2012
    ..However, CYP2C8 was also recently found to be involved. Our aim was to study the effects of selective CYP2C8 and CYP3A4 inhibitors on the pharmacokinetics of montelukast...
  37. doi request reprint Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate
    Marja K Pasanen
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Pharmacogenet Genomics 18:921-6. 2008
    ..In conclusion, the low activity SLCO1B1 c.521CC genotype is associated with an increased cholesterol synthesis rate. The short-term effects of statins on cholesterol homeostasis were not associated with the SLCO1B1 polymorphism...
  38. doi request reprint Effect of SLCO1B1 polymorphism on the plasma concentrations of bile acids and bile acid synthesis marker in humans
    Xiaoqiang Xiang
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Pharmacogenet Genomics 19:447-57. 2009
    ..Organic anion transporting polypeptide 1B1 (OATP1B1, encoded by SLCO1B1) is a sinusoidal influx transporter of human hepatocytes. Our aim was to characterize the role of OATP1B1 in the hepatic uptake of bile acids in vivo...
  39. pmc Effect of rifampicin on the pharmacokinetics of pioglitazone
    Tiina Jaakkola
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Br J Clin Pharmacol 61:70-8. 2006
    ..Rifampicin is a potent inducer of several CYP enzymes and our objective was to study its effects on the pharmacokinetics of pioglitazone in humans...
  40. doi request reprint Celecoxib is a CYP1A2 inhibitor in vitro but not in vivo
    Marjo J Karjalainen
    Department of Clinical Pharmacology, University of Helsinki, Helsinki, Finland
    Eur J Clin Pharmacol 64:511-9. 2008
    ..We recently discovered that rofecoxib is a potent mechanism-based inhibitor of CYP1A2. The effect of the widely used cyclo-oxygenase-2 selective non-steroidal anti-inflammatory drug celecoxib on CYP1A2 activity has not been reported...
  41. ncbi request reprint Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance
    Carl Kyrklund
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Clin Pharmacol Ther 73:538-44. 2003
    ..Pravastatin pharmacokinetics differs from those of these 3 statins, which are extensively metabolized. Our aim was to study the effects of gemfibrozil on the pharmacokinetics of pravastatin...
  42. pmc The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects
    Mikko Niemi
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Br J Clin Pharmacol 57:441-7. 2004
    ....
  43. pmc Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects
    Mikko Niemi
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Br J Clin Pharmacol 56:427-32. 2003
    ..Our aim was to investigate the effects of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide, a novel short-acting antidiabetic drug...
  44. pmc Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects
    Carl Kyrklund
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Br J Clin Pharmacol 57:181-7. 2004
    ..This study was conducted to investigate the effect of rifampicin on the pharmacokinetics of pravastatin...
  45. ncbi request reprint Effect of albumin and cytosol on enzyme kinetics of tolbutamide hydroxylation and on inhibition of CYP2C9 by gemfibrozil in human liver microsomes
    Jun Sheng Wang
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Haartmaninkatu 4, FIN 00290 Helsinki, Finland
    J Pharmacol Exp Ther 302:43-9. 2002
    ..The present findings suggest that the addition of Hsa and Hlc to microsomal incubation media may yield enzyme kinetic estimates more comparable with in vivo results...
  46. ncbi request reprint Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors
    Tiina Jaakkola
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Basic Clin Pharmacol Toxicol 99:44-51. 2006
    ....
  47. ncbi request reprint The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone
    Aleksi Tornio
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Eur J Clin Pharmacol 62:645-51. 2006
    ..Zopiclone is a short acting hypnotic, which is metabolised by cytochrome P450 (CYP) 3A4 and 2C8 in vitro. We studied the possible effect of gemfibrozil, an inhibitor of CYP2C8, on the pharmacokinetics and pharmacodynamics of zopiclone...
  48. ncbi request reprint Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine
    Janne T Backman
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Eur J Clin Pharmacol 62:451-61. 2006
    ..Our aim was to characterise the inducibility of cytochrome P450 (CYP) 1A2 by rifampicin, using tizanidine and caffeine as probe drugs for presystemic and systemic CYP1A2-mediated metabolism...
  49. ncbi request reprint Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine
    Janne T Backman
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Eur J Clin Pharmacol 64:17-24. 2008
    ..We studied the effects of gender and smoking on the pharmacokinetics and effects of the cytochrome P450 (CYP) 1A2 substrate tizanidine...
  50. ncbi request reprint SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid
    Marja K Pasanen
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Pharmacogenet Genomics 16:873-9. 2006
    ..This study aimed to investigate the effects of genetic polymorphism in the SLCO1B1 gene encoding OATP1B1 on the pharmacokinetics of simvastatin...
  51. pmc Grapefruit juice markedly increases the plasma concentrations and antiplatelet effects of ticagrelor in healthy subjects
    Mikko T Holmberg
    Department of Clinical Pharmacology, University of Helsinki and HUSLAB, Helsinki, Finland
    Br J Clin Pharmacol 75:1488-96. 2013
    ..This study examined the effects of grapefruit juice on the new P2Y12 inhibitor ticagrelor, which is a substrate of CYP3A4 and P-glycoprotein...
  52. doi request reprint Gender, but not CYP7A1 or SLCO1B1 polymorphism, affects the fasting plasma concentrations of bile acids in human beings
    Xiaoqiang Xiang
    Department of Clinical Pharmacology, University of Helsinki, Helsinki, Finland
    Basic Clin Pharmacol Toxicol 110:245-52. 2012
    ..Common genetic variability in CYP7A1 is unlikely to play a significant role in cholesterol metabolism and bile acid homeostasis under normal physiological conditions...
  53. ncbi request reprint Effect of ciprofloxacin on the pharmacokinetics of ropivacaine
    Mika J Jokinen
    Department of Anaesthesia and Intensive Care, Helsinki University Central Hospital, P O Box 340, 00029 HUS, Finland
    Eur J Clin Pharmacol 58:653-7. 2003
    ..6 mg/kg ropivacaine intravenously over 30 min. Ropivacaine, 3-hydroxyropivacaine (3-OH-ropivacaine), and (S)-2',6'-pipecoloxylidide (PPX) in venous plasma and urine were measured for up to 12 h and 24 h, respectively...
  54. pmc Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide
    Lauri I Kajosaari
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Br J Clin Pharmacol 58:390-6. 2004
    ..Our aim was to investigate the effects of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide...
  55. doi request reprint Effect of ABCB1 haplotypes on the pharmacokinetics and renin-inhibiting effect of aliskiren
    Tuija Tapaninen
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, PO Box 705, 00029 HUS, Helsinki, Finland
    Eur J Clin Pharmacol 66:865-70. 2010
    ..This study aimed to investigate the possible effects of ABCB1 haplotypes on the pharmacokinetics and renin-inhibiting effect of aliskiren...
  56. ncbi request reprint Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population
    Marja K Pasanen
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, PO Box 340, Helsinki, 00029 HUS, Finland
    Eur J Clin Pharmacol 62:409-15. 2006
    ....
  57. ncbi request reprint Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide
    Mikko Niemi
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Clin Pharmacol Ther 74:380-7. 2003
    ..Our objective was to investigate the effects of genetic polymorphisms of cytochrome P450 (CYP) 2C8 on the pharmacokinetics and pharmacodynamics of the meglitinide analog antidiabetic drug repaglinide...
  58. ncbi request reprint Global analysis of genetic variation in SLCO1B1
    Marja K Pasanen
    University of Helsinki, Department of Clinical Pharmacology, Helsinki University Central Hospital, PO Box 340, FIN 00029 HUS, Helsinki, Finland
    Pharmacogenomics 9:19-33. 2008
    ..The aim of this study was to investigate the diversity of the SLCO1B1 gene at the global level...
  59. ncbi request reprint Effect of itraconazole on the pharmacokinetics of atenolol
    Jari J Lilja
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Basic Clin Pharmacol Toxicol 97:395-8. 2005
    ..166) suggesting a slight increase of atenolol bioavailability. It can be concluded that itraconazole does not have a clinically relevant effect on the pharmacokinetics of atenolol...
  60. ncbi request reprint Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively
    Xia Wen
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Drug Metab Dispos 30:631-5. 2002
    ..In conclusion, trimethoprim and sulfamethoxazole can be used as selective inhibitors of CYP2C8 and CYP2C9 in in vitro studies. In humans, trimethoprim and sulfamethoxazole may inhibit the activities of CYP2C8 and CYP2C9, respectively...
  61. ncbi request reprint Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites
    Janne T Backman
    Department of Clinical Pharmacology, University of Helsinki, Finland
    Clin Pharmacol Ther 78:154-67. 2005
    ..The pharmacokinetic interactions of the widely used statin atorvastatin with fibrates and enzyme inducers are not known. Therefore we studied the effects of rifampin (INN, rifampicin) and gemfibrozil on the pharmacokinetics of atorvastatin...
  62. ncbi request reprint Gemfibrozil greatly increases plasma concentrations of cerivastatin
    Janne T Backman
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Finland
    Clin Pharmacol Ther 72:685-91. 2002
    ..Our aim was to study the effect of gemfibrozil on cerivastatin pharmacokinetics...
  63. ncbi request reprint Orange juice substantially reduces the bioavailability of the beta-adrenergic-blocking agent celiprolol
    Jari J Lilja
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Haartmaninkatu 4, FIN 00290, Finland
    Clin Pharmacol Ther 75:184-90. 2004
    ..Our objective was to investigate the effect of orange juice on the pharmacokinetics of celiprolol in healthy subjects...
  64. doi request reprint High performance liquid chromatography-tandem mass spectrometry for the determination of bile acid concentrations in human plasma
    Xiaoqiang Xiang
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    J Chromatogr B Analyt Technol Biomed Life Sci 878:51-60. 2010
    ..In conclusion, this method is suitable for the simultaneous quantification of individual bile acids in human plasma...
  65. ncbi request reprint Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol
    Jari J Lilja
    Department of Clinical Pharmacology, University of Helsinki, Haartmaninkatu 4, FIN 00290 Helsinki, Finland
    Clin Pharmacol Ther 73:192-8. 2003
    ..Our objective was to evaluate the effects of itraconazole and grapefruit juice on the pharmacokinetics of the beta-adrenergic receptor-blocking agent celiprolol in healthy volunteers...
  66. doi request reprint Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren
    Tuija Tapaninen
    Department of Clinical Pharmacology, University of Helsinki, Helsinki, Finland
    Eur J Clin Pharmacol 66:497-502. 2010
    ..This study aimed to investigate the effect of rifampicin, an inducer of CYP3A4 and P-glycoprotein, on the pharmacokinetics and pharmacodynamics of aliskiren, a renin inhibitor used in the treatment of hypertension...
  67. pmc Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide
    Jari J Lilja
    Department of Clinical Pharmacology, University of Helsinki, Helsinki, Finland
    Br J Clin Pharmacol 63:732-40. 2007
    ..Our objective was to evaluate whether the P-glycoprotein inhibitor, clarithromycin, increases and the putative OATP2B1 inhibitor, grapefruit juice, decreases plasma concentrations of glibenclamide...
  68. ncbi request reprint Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2
    Marika T Granfors
    Department of Clinical Pharmacology, University of Helsinki, and Helsinki University Central Hospital, Helsinki, Finland
    Clin Pharmacol Ther 78:400-11. 2005
    ..Our objective was to study the effect of combined OCs, containing ethinyl estradiol (INN, ethinylestradiol) and gestodene, on CYP1A2 activity, as well as their interaction potential with tizanidine...
  69. doi request reprint Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations
    Anne M Filppula
    Department of Clinical Pharmacology, University of Helsinki, Helsinki, Finland
    Drug Metab Dispos 39:904-11. 2011
    ..In conclusion, CYP2C8 plays a major role in the main metabolic pathway of montelukast at clinically relevant montelukast concentrations in vitro...
  70. pmc No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone
    Annikka Kalliokoski
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Br J Clin Pharmacol 65:78-86. 2008
    ....
  71. pmc Orange and apple juice greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren
    Tuija Tapaninen
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Br J Clin Pharmacol 71:718-26. 2011
    ..The aim of this study was to investigate the effects of orange juice and apple juice on the pharmacokinetics and pharmacodynamics of aliskiren...
  72. ncbi request reprint Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole
    Kari Raaska
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Finland
    Clin Pharmacol Ther 72:362-9. 2002
    ..Our objective was to examine the effects of itraconazole on the pharmacokinetics and cortisol-suppressant activity of budesonide administered by inhalation...
  73. ncbi request reprint Effect of itraconazole on the pharmacokinetics of inhaled lidocaine
    Mika H Isohanni
    Department of Anaesthesia, Diacor Hospital, Helsinki, Finland
    Basic Clin Pharmacol Toxicol 95:120-3. 2004
    ..The clinical implication of this study is that no lidocaine dosage adjustments are necessary if it is used to prepare the airway prior to endoscopic procedures or intubation in patients using itraconazole or other inhibitors of CYP3A4...
  74. ncbi request reprint Effect of fluconazole on the pharmacokinetics and pharmacodynamics of nateglinide
    Mikko Niemi
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Finland
    Clin Pharmacol Ther 74:25-31. 2003
    ..Our aim was to investigate the possible effects of fluconazole on the pharmacokinetics and pharmacodynamics of nateglinide, a new short-acting meglitinide analog antidiabetic drug...
  75. ncbi request reprint Prescription drugs during pregnancy and lactation--a Finnish register-based study
    Heli Malm
    Department of Medical Genetics, The Family Federation of Finland, Helsinki, Finland
    Eur J Clin Pharmacol 59:127-33. 2003
    ..To examine the use of prescription drugs in Finnish women before and during pregnancy and lactation...
  76. ncbi request reprint Risks associated with selective serotonin reuptake inhibitors in pregnancy
    Heli Malm
    Teratology Information Service, HUSLAB, Helsinki University Central Hospital, Finland
    Obstet Gynecol 106:1289-96. 2005
    ..To study the effects of selective serotonin reuptake inhibitors (SSRIs) on pregnancy outcome...
  77. pmc Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects
    Janne T Backman
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Br J Clin Pharmacol 62:345-57. 2006
    ..Case reports suggest an interaction between rofecoxib and the CYP1A2 substrate tizanidine. Our objectives were to explore the extent and mechanism of this possible interaction and to determine the CYP1A2 inhibitory potency of rofecoxib...
  78. pmc Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin
    Jari J Lilja
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Br J Clin Pharmacol 58:56-60. 2004
    ..Simvastatin, a substrate for CYP3A4, is extensively metabolized during the first pass. Our aim was to investigate the effect of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin...
  79. ncbi request reprint Effect of caffeine-containing versus decaffeinated coffee on serum clozapine concentrations in hospitalised patients
    Kari Raaska
    Department of Clinical Pharmacology, University of Helsinki, FIN 00290 Helsinki, Finland
    Basic Clin Pharmacol Toxicol 94:13-8. 2004
    ..g. to genetic factors. The increase in serum clozapine concentration was most likely due to the inhibition of the CYP1A2 enzyme by caffeine...
  80. ncbi request reprint Rofecoxib is a potent, metabolism-dependent inhibitor of CYP1A2: implications for in vitro prediction of drug interactions
    Marjo J Karjalainen
    Department of Clinical Pharmacology, University of Helsinki, Haartmaninkatu 4, FIN 00290 Helsinki, Finland
    Drug Metab Dispos 34:2091-6. 2006
    ..The results provide a mechanistic explanation for the interactions of rofecoxib with CYP1A2 substrates and may partially explain its nonlinear pharmacokinetics...
  81. pmc Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects
    Jari J Lilja
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Br J Clin Pharmacol 59:433-9. 2005
    ..Case reports suggest that gemfobrozil can increase the anticoagulant effect of warfarin. Because gemfibrozil inhibits CYP2C9 in vitro, we studied its effects on the pharmacokinetics and pharmacodynamics of racemic warfarin...
  82. ncbi request reprint Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17
    Mikko Niemi
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Pharmacogenet Genomics 15:303-9. 2005
    ..The aim was to investigate whether polymorphisms in the SLCO1B1 gene, encoding the hepatic uptake transporter OATP1B1, influence the short-term effects of pravastatin on cholesterol synthesis...
  83. ncbi request reprint Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life
    Teijo I Saari
    Department of Anesthesiology and Intensive Care, University of Turku, Turku, Finland
    Clin Pharmacol Ther 80:502-8. 2006
    ..Concomitant administration of alfentanil and CYP3A inhibitors may lead to clinically important drug interactions. We investigated the possible interactions between alfentanil and orally administered voriconazole and terbinafine...
  84. pmc Effects of the antifungals voriconazole and fluconazole on the pharmacokinetics of s-(+)- and R-(-)-Ibuprofen
    Ville Veikko Hynninen
    Department of Anesthesiology and Intensive Care, Turku University Hospital, Finland
    Antimicrob Agents Chemother 50:1967-72. 2006
    ..A reduction of the ibuprofen dosage should be considered when ibuprofen is coadministered with voriconazole or fluconazole, especially when the initial ibuprofen dose is high...
  85. ncbi request reprint Cancer incidence among patients using antiepileptic drugs: a long-term follow-up of 28,000 patients
    Anne Lamminpää
    Orton Hospital, Tenholantie 10, 00280 Helsinki, Finland
    Eur J Clin Pharmacol 58:137-41. 2002
    ..The purpose of the study was to find out whether there is an association between use of enzyme-inducing antiepileptic medicines and cancer...
  86. ncbi request reprint Voriconazole and fluconazole increase the exposure to oral diazepam
    Teijo I Saari
    Department of Anesthesiology, Intensive Care, Emergency Care and Pain Medicine, University of Turku, P O Box 52, Kiinamyllynkatu 4 8, 20520, Turku, Finland
    Eur J Clin Pharmacol 63:941-9. 2007
    ..We assessed the effect of voriconazole and fluconazole on the pharmacokinetics and pharmacodynamics of diazepam...
  87. ncbi request reprint Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl
    Teijo I Saari
    Department of Anaesthesiology, Intensive Care, Emergency Care and Pain Medicine, University of Turku, P O Box 52, Kiinamyllynkatu 4 8, FI 20520, Turku, Finland
    Eur J Clin Pharmacol 64:25-30. 2008
    ..Recent reports suggest that concomitant administration of CYP3A inhibitors with fentanyl may lead to dangerous drug interactions...
  88. ncbi request reprint Effect of voriconazole on the pharmacokinetics of diclofenac
    Ville Veikko Hynninen
    Department of Pharmacology, Drug Development and Therapeutics, University of Turku and Turku University Hospital, Turku, Finland
    Fundam Clin Pharmacol 21:651-6. 2007
    ..The clinical importance of the interaction between voriconazole and diclofenac remains to be studied, but lower doses of diclofenac may be adequate for patients receiving voriconazole...
  89. ncbi request reprint Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression
    Mia Hedman
    Hospital for Children and Adolescents and Department of Clinical Pharacology, University of Helsinki, Finland
    Clin Pharmacol Ther 75:101-9. 2004
    ..Our aim was to determine the single-dose pharmacokinetics and short-term safety of pravastatin in children undergoing regular triple-drug immunosuppressive therapy after cardiac transplantation...
  90. ncbi request reprint High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)
    Mikko Niemi
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Pharmacogenetics 14:429-40. 2004
    ..No significant associations were found between OATP-B, MRP2 or MDR1 polymorphisms and the pharmacokinetics of pravastatin. These results suggest that haplotypes are more informative in predicting the OATP-C phenotype than single SNPs...